Brokerages Set Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Price Target at $35.00

Shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT) have been assigned an average recommendation of “Hold” from the five brokerages that are presently covering the stock, Marketbeat reports. Five research analysts have rated the stock with a hold rating. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $39.25.

Several equities research analysts have recently weighed in on CALT shares. Stifel Nicolaus reiterated a “hold” rating and issued a $40.00 price target (down from $55.00) on shares of Calliditas Therapeutics AB (publ) in a report on Tuesday, May 28th. HC Wainwright reiterated a “neutral” rating and set a $39.00 target price on shares of Calliditas Therapeutics AB (publ) in a research report on Tuesday, May 28th. Citigroup restated a “neutral” rating and issued a $39.00 price target on shares of Calliditas Therapeutics AB (publ) in a report on Friday, May 31st. Jefferies Financial Group reaffirmed a “hold” rating and issued a $39.00 price target (down previously from $58.00) on shares of Calliditas Therapeutics AB (publ) in a research note on Tuesday, May 28th. Finally, Lifesci Capital cut shares of Calliditas Therapeutics AB (publ) from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 28th.

Calliditas Therapeutics AB (publ) Trading Up 1.3 %

CALT stock opened at $39.32 on Wednesday. Calliditas Therapeutics AB has a twelve month low of $15.25 and a twelve month high of $41.90. The stock has a market capitalization of $1.17 billion, a price-to-earnings ratio of -21.25 and a beta of 1.77. The company has a quick ratio of 2.62, a current ratio of 2.69 and a debt-to-equity ratio of 8.46. The firm’s fifty day simple moving average is $38.93 and its two-hundred day simple moving average is $28.46.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.09. Calliditas Therapeutics AB (publ) had a negative net margin of 40.19% and a negative return on equity of 160.87%. The company had revenue of $52.36 million for the quarter, compared to the consensus estimate of $42.89 million. During the same period in the prior year, the firm posted ($0.33) EPS. As a group, analysts anticipate that Calliditas Therapeutics AB will post -0.86 earnings per share for the current year.

Institutional Trading of Calliditas Therapeutics AB (publ)

A hedge fund recently bought a new stake in Calliditas Therapeutics AB (publ) stock. Optiver Holding B.V. purchased a new position in Calliditas Therapeutics AB (publ) (NASDAQ:CALT) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 980 shares of the company’s stock, valued at approximately $25,000. Institutional investors and hedge funds own 2.83% of the company’s stock.

Calliditas Therapeutics AB (publ) Company Profile

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.